PT-BR: Radioterapia PSMA-ligante dirigida com Lutécio 177 como um tratamento para câncer de próstata resistente a castração: uma revisão sistemática
DOI:
https://doi.org/10.11606/issn.1679-9836.v100i4p391-402Palavras-chave:
Neoplasias da próstata, 177Lu-PSMA, Câncer de próstata resistente à castração, Eficácia, Metástase neoplásica, Antígeno de membrana específico da próstata, Terapia com radioligantes, Segurança, Dosimetria, Medicina nuclearResumo
O câncer de próstata é o segundo mais prevalente no mundo, sendo uma importante causa de mortalidade dentre homens idosos. Sua forma mais séria é o câncer metastático resistente a terapia hormonal, sendo difícil de controlar pois não responde tanto a quimioterapia quanto a privação de androgénos. Um novo tratamento, baseado em moléculas ligantes de PSMA, quelado ao átomo Lutécio-177, é uma terapia potencial para esse perfil de paciente, com evidências que esta causa regressão tumoral. O objetivo dessa revisão sistemática é avaliar a segurança e eficiência dessa nova terapia baseada na literatura atual
Downloads
Referências
Torre LA, Siegel RL, Ward EM, Jemal A. global cancer incidence and mortality rates and trends--an update. Cancer Epidemiol Biomarkers Prev. 2015;25(1):16-27. doi: 10.1158/1055-9965.EPI-15-0578.
Tourinho-Barbosa RR, Pompeo ACL, Glina S. Prostate cancer in Brazil and Latin America: epidemiology and screening. Int Braz J Urol. 2016;42(6):1081-90. doi: 10.1590/S1677-5538.
Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. 177Lutetium-PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64(1):52-60. doi: 10.1002/jmrs.227.
Pezaro CJ, Marciscano AE, Madan RA. The winds of change: emerging therapeutics in prostate cancer. Am Soc Clin Oncol Educ Book. 2018;(38):382-90. doi: 10.1200/EDBK_201295.
Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54(7):1807-11. Available from: https://cancerres.aacrjournals.org/content/canres/54/7/1807.full.pdf.
Rahbar K, Ahmadzadehfar H, Kratochwil C. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85–90. doi: 10.2967/jnumed.116.183194.
Filss C, Heinzel A, Miiller B, Vogg A, Langen K-J, Mottaghy F. Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy. Nuklearmedizin. 2018;57(01):19–25. doi: 10.3413/Nukmed-0937-17-10
Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M, et al. Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(2):243–6. DOI: 10.1007/s00259-017-3877-z.
Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schäfers M, Essler M, et al. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2017;45(1):12–9. doi: 10.1007/s00259-017-3848-4.
Bräuer A, Grubert LS, Roll W, Schrader AJ, Schäfers M, Bögemann M, et al. 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44(10):1663–70. doi: http://dx.doi.org/10.1007/s00259-017-3751-z.
Fendler WP, Reinhardt S, Ilhan H, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8(2):3581–3590. doi: 10.18632/oncotarget.12240.
Okamoto S, Thieme A, Allmann J, D’Alessandria C, Maurer T, Retz M, et al. Radiation dosimetry for 177 Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions. J Nucl Med. 2016;58(3):445–50. doi: 10.2967/jnumed.116.178483.
Ferdinandus J, Eppard E, Gaertner FC, Kürpig S, Fimmers R, Yordanova A, et al. Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177 Lu-PSMA-617. J Nucl Med. 2016;58(2):312–9. doi: 10.2967/jnumed.116.178228.
Demir M, Abuqbeitah M, Uslu-Beşli L, Yıldırım Ö, Yeyin N, Çavdar I, et al. Evaluation of radiation safety in177Lu-PSMA therapy and development of outpatient treatment protocol. J Radiol Prot. 2016;36(2):269–78. doi: 10.1088/0952-4746/36/2/269.
Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, et al. Radioligand Therapy With 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. Clin Nucl Med. 2016Jul;41(7):522–8. doi: 10.1097/RLU.0000000000001240.
Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, et al. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016;57(9):1334–8. doi: 10.2967/jnumed.116.173757.
Hohberg M, Eschner W, Schmidt M, Dietlein M, Kobe C, Fischer T, et al. Lacrimal glands may represent organs at risk for radionuclide therapy of prostate cancer with [177Lu]DKFZ-PSMA-617. Mol Imaging Biol. 2016;18(3):437–45. doi: 10.1007/s11307-016-0942-0.
Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7(11):12477–12488. doi: 10.18632/oncotarget.7245
Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-Labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57(7):1006–13. doi: 10.2967/jnumed.115.168443.
Kabasakal L, Abuqbeitah M, Aygün A, Yeyin N, Ocak M, Demirci E, et al. Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(13):1976–83. doi: 10.1007/s00259-015-3125-3.
Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol. 2010;28(17):2810–6. doi: 10.1200/JCO.2009.25.7311.
Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016;41(7):522–8. doi: 10.1097/RLU.0000000000001240.
Yordanova A, Linden P, Hauser S, Meisenheimer M, Kürpig S, Feldmann G, et al. Outcome and safety of rechallenge [177Lu]-PSMA-617 in patients with metastatic prostate cancer. Eur J Nuclear Med Mol Imaging. 2018;46(5):1073–80. doi: 10.1007/s00259-018-4222-x
Yilmaz B, Nisli S, Ergul N, Gursu RU, Acikgoz O, Çermik TF. Effect of External Cooling on 177Lu-PSMA Uptake by the Parotid Glands. J Nuclear Med. 2019;60(10):1388–93. doi: 10.2967/jnumed.119.226449
Gafita A, Rauscher I, Retz M, Knorr K, Heck M, Wester H-J, et al. Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer. J Nuclear Med. 2018;60(5):644–8. doi: 10.2967/jnumed.118.215715
Heck MM, Tauber R, Schwaiger S, Retz M, D’Alessandria C, Maurer T, et al. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019;75(6):920–6. doi: 10.1016/j.eururo.2018.11.016
van Kalmthout L, Braat A, Lam M, van Leeuwaarde R, Krijger G, Ververs T, et al. First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands. Clin Nuclear Med. 2019;44(6):446–51. doi: 10.1097/RLU.0000000000002561
Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy. J Nuclear Med. 2019;60(7):955–62. doi: 10.2967/jnumed.118.216820
Yadav MP, Ballal S, Bal C, Sahoo RK, Damle NA, Tripathi M, et al. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients. Clin Nuclear Med. 2020;45(1):19–31. doi: 10.1097/RLU.0000000000002833.
Özkan A, Uçar B, Seymen H, Yildiz Yarar Y, Falay FO, Demirkol MO. Posttherapeutic Critical Organ Dosimetry of Extensive 177Lu-PSMA Inhibitor Therapy With Metastatic Castration-Resistant Prostate Cancer. Clin Nuclear Med. 2020;45(4):288–91. DOI: 10.1097/RLU.0000000000002942.
Hofman MS, Emmett L, Sandhu SK, Iravani A, Joshua AM, Goh JC, et al. TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603). J Clin Oncol. 2020;38(15_suppl):5500–. doi: 10.1200/JCO.2020.38.15_suppl.5500.
Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang S-P, Kong G, et al. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. J Nuclear Med. 2019;61(6):857–65. doi: 10.2967/jnumed.119.236414.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2021 Lucca Paolo Hsu Helmich, Marcelo Augusto Magalhães de Arruda, Marcelo Tatit Sapienza
Este trabalho está licenciado sob uma licença Creative Commons Attribution-ShareAlike 4.0 International License.
